A Pharmaceutical Guru’s Huge Buy, and Why You Should Too
Patrick Cox and I spent the better part of Wednesday afternoon visiting Teva's chairman, Dr. Phillip Frost, at his Miami office. Dr. Frost became vice chairman of Teva upon its acquisition of Miami pharmaceutical company Ivax Corp., which he sold to Teva in 2006 for over $7 billion. He became chairman in 2010, and was re-elected to the position last month.
This personal visit was, to put it mildly, a wonderful opportunity to learn what is on the mind of one of the pharmaceutical industry's great investors and leaders.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.